Thursday, May 12, 2011 9:07:00 AM
IMO $20 is way too optimistic, $15'ish is more like it.
Remember that the panel voted 6-7 NO on the crucial question of recurrence benefit. In fairness, perhaps that was simply because OPTR got greedy and asked for too much; instead of "prevention of recurrence" something like "reduction in the risk of recurrence" would have been more acceptable to the panel.
Whatever the answer, it's an important factor to consider. No doubt the company has been negotiating with the FDA about the exact label language, and hopefully we get at least "30-day recurrence superiority."
Best of luck to all.
FEATURED CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • Oct 8, 2024 8:00 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM